In support of this concept, a phase I clinical trial demonstrated improvement in DAS28 in RA patients transfused with autologous tolerogenic DCs modified in vitro with an NF-kB inhibitor51, and this was associated with a decrease in antigen-specific effector T cells and serum pro-inflammatory cytokines, and an increase in regulatory T cells. Here, NFKB1 is linked to rheumatoid arthritis.